Search: onr:"swepub:oai:DiVA.org:uu-275569" > Clinical Use of Can...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05442naa a2200565 4500 | |
001 | oai:DiVA.org:uu-275569 | |
003 | SwePub | |
008 | 160204s2016 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2755692 URI |
024 | 7 | a https://doi.org/10.1097/IGC.00000000000005862 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Soletormos, Gyorgyu Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.4 aut |
245 | 1 0 | a Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers |
264 | 1 | c 2016 |
338 | a electronic2 rdacarrier | |
520 | a Objective:To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial varian cancer. Methods: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. Results: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. Conclusions: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng |
653 | a Ovarian cancer | |
653 | a CA125 | |
653 | a HE4 | |
653 | a Screening | |
653 | a Differential diagnosis | |
653 | a Monitoring | |
700 | 1 | a Duffy, Michael J.u St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland.4 aut |
700 | 1 | a Abu Hassan, Suher Othmanu Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.4 aut |
700 | 1 | a Verheijen, Rene H. M.u Univ Med, Ctr Utrecht, Dept Gynecol Oncol, Utrecht, Netherlands.4 aut |
700 | 1 | a Tholander, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)betho227 |
700 | 1 | a Bast, Robert C., Jr.u Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gynecol Med Oncol, Houston, TX 77030 USA.4 aut |
700 | 1 | a Gaarenstroom, Katja N.u Leiden Univ, Med Ctr, Dept Gynecol, Leiden, Netherlands.4 aut |
700 | 1 | a Sturgeon, Catharine M.u Royal Infirm Edinburgh NHS Trust, Dept Clin Biochem, Edinburgh, Midlothian, Scotland.4 aut |
700 | 1 | a Bonfrer, Johannes M.u PUM Netherlands Senior Experts, Senior Expert Clin Labs, Heemstede, Netherlands.4 aut |
700 | 1 | a Petersen, Per Hyltoftu Univ Bergen, Norwegian Qual Improvement Primary Care Labs NOKL, Sect Gen Practice, Bergen, Norway.4 aut |
700 | 1 | a Troonen, Hugou Abbott, Limburg, Germany.4 aut |
700 | 1 | a CarloTorre, Gianu Ctr Ippocrate, Bogliasco, Italy.4 aut |
700 | 1 | a Kulpa, Jan Kantyu M Sklodowska Curie Mem Inst, Cracow Div, Ctr Oncol, Dept Clin Biochem, Krakow, Poland.4 aut |
700 | 1 | a Tuxen, Malgorzata K.u Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark.4 aut |
700 | 1 | a Molina, Raphaelu Hosp Clin Barcelona, Biochem Lab, Barcelona, Spain.4 aut |
710 | 2 | a Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.b St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland.4 org |
773 | 0 | t International Journal of Gynecological Cancerg 26:1, s. 43-51q 26:1<43-51x 1048-891Xx 1525-1438 |
856 | 4 | u https://doi.org/10.1097/IGC.0000000000000586y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:900469/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-275569 |
856 | 4 8 | u https://doi.org/10.1097/IGC.0000000000000586 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view